Company / Revenue
Matinas BioPharma Holdings, Inc. Revenue History
FY2015-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$3.2M
FY2023
5-year range
$33.0K / $3.2M
FY2019-FY2023
Trend
+9560.6%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue changed +9561% YoY in FY2023, a notable deviation from the 7-year average annual change of +1339%.
Based on SEC 10-K filings.
$3M in FY2023 with a 5-year CAGR of +84.4%.
Improved from $33,000 to $3M over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- +172.1%
- 5-Year CAGR
- +84.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +84.4%, indicating consistent growth.
- In FY2023, revenue increased 9560.6% year-over-year.
- Lowest revenue in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | $3.2M | +9560.6% |
| FY2022 | $33.0K | +0.0% |
| FY2021 | $33.0K | -79.2% |
| FY2020 | $158.3K | +32.2% |
| FY2019 | $119.8K | -20.0% |
| FY2018 | $149.7K | -23.0% |
| FY2017 | $194.5K | - |
| FY2016 | $0 | -100.0% |
| FY2015 | $194.5K | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026